Onassis Holdings Launches $75 Million Regulation A+ Financing Round with Dalmore Group

Onassis Holdings (OTC: ONSS), a biotechnology holding company focused on longevity and rejuvenation technologies, has announced the launch of a Regulation A+ financing round through an agreement with Dalmore Group. This financing initiative allows the company to raise up to $75 million annually from the public market, providing significant capital to support its research and development efforts in epigenetic reprogramming.

The partnership with Dalmore Group brings substantial expertise to the financing effort, as Dalmore has onboarded more than 270 Regulation A+ issuers since 2021 and possesses over 16 years of experience in the field. Dalmore's comprehensive services include marketing and public relations support, marketplace syndication, and secondary trading solutions for issuers, leveraging their strong market relationships to maximize the success of the financing round.

Onassis Holdings specializes in epigenetic reprogramming technologies aimed at longevity and cellular rejuvenation. The company's subsidiary, Ananda Labs, is focused on developing groundbreaking therapies based on patented proteins that rejuvenate elderly cells while maintaining their distinct properties. This innovative approach has significant implications for the treatment of age-related diseases and the broader field of regenerative medicine.

The Regulation A+ financing mechanism provides Onassis Holdings with access to public capital markets without the traditional complexities of a full initial public offering. This approach democratizes investment opportunities, allowing individual investors to participate in early-stage biotechnology ventures that were previously accessible primarily to institutional investors. The potential $75 million annual raise could accelerate the development of Ananda Labs' therapies, potentially bringing new treatments to market faster.

For the biotechnology industry, this financing round represents continued investor interest in longevity and rejuvenation technologies, a sector that has gained significant attention in recent years. The success of this offering could encourage other biotech companies to pursue similar financing strategies, potentially increasing innovation and competition in the field of epigenetic research and cellular therapy.

More information about Onassis Holdings and its technologies is available at https://www.onassis-holdings.com/. The regulatory framework and market infrastructure supporting this financing are provided through specialized communications platforms such as those offered by the Dynamic Brand Portfolio, which includes advanced wire-grade press release syndication services for public and private companies.